BR112015019719A2 - Proteínas melhoradas de ligação ao tnf - Google Patents

Proteínas melhoradas de ligação ao tnf

Info

Publication number
BR112015019719A2
BR112015019719A2 BR112015019719A BR112015019719A BR112015019719A2 BR 112015019719 A2 BR112015019719 A2 BR 112015019719A2 BR 112015019719 A BR112015019719 A BR 112015019719A BR 112015019719 A BR112015019719 A BR 112015019719A BR 112015019719 A2 BR112015019719 A2 BR 112015019719A2
Authority
BR
Brazil
Prior art keywords
binding proteins
tnf
enhanced tnf
enhanced
presented
Prior art date
Application number
BR112015019719A
Other languages
English (en)
Inventor
Ghayur Tariq
Ambrosi Dominic
B Deora Arun
Hegde Subramanya
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112015019719A2 publication Critical patent/BR112015019719A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROTEÍNAS MELHORADAS DE LIGAÇÃO AO TNF. São apresentadas proteínas de ligação ao TNF e métodos de tratamento utilizando as mesmas. Também são apresentados ácidos nucleicos que codificam as proteínas de ligação e vetores de expressão recombinantes e células hospedeiras para produzir tais proteínas de ligação.
BR112015019719A 2013-03-15 2014-03-14 Proteínas melhoradas de ligação ao tnf BR112015019719A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788113P 2013-03-15 2013-03-15
PCT/US2014/027118 WO2014152247A1 (en) 2013-03-15 2014-03-14 Improved tnf binding proteins

Publications (1)

Publication Number Publication Date
BR112015019719A2 true BR112015019719A2 (pt) 2017-08-22

Family

ID=50489423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019719A BR112015019719A2 (pt) 2013-03-15 2014-03-14 Proteínas melhoradas de ligação ao tnf

Country Status (10)

Country Link
US (1) US20140294813A1 (pt)
EP (1) EP2970458A1 (pt)
JP (1) JP2016516041A (pt)
CN (1) CN105189550A (pt)
AU (1) AU2014239972A1 (pt)
BR (1) BR112015019719A2 (pt)
CA (1) CA2898676A1 (pt)
HK (1) HK1218920A1 (pt)
MX (1) MX2015012281A (pt)
WO (1) WO2014152247A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180594A (es) * 2016-06-02 2019-07-29 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
RU2020117698A (ru) 2017-12-01 2022-01-04 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
CN114686450B (zh) * 2020-12-28 2024-04-16 苏州引航生物科技有限公司 经修饰的维生素d羟化酶突变体及其应用
JP2024506012A (ja) 2021-02-04 2024-02-08 上海森▲輝▼医▲葯▼有限公司 グルココルチコイド受容体アゴニストの薬物複合体及びその医薬的応用
WO2023025248A1 (zh) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0708585D0 (en) * 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US20100233079A1 (en) * 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20140015139A (ko) * 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도

Also Published As

Publication number Publication date
AU2014239972A1 (en) 2015-10-08
HK1218920A1 (zh) 2017-03-17
WO2014152247A8 (en) 2015-09-03
JP2016516041A (ja) 2016-06-02
WO2014152247A1 (en) 2014-09-25
EP2970458A1 (en) 2016-01-20
CN105189550A (zh) 2015-12-23
MX2015012281A (es) 2015-12-16
CA2898676A1 (en) 2014-09-25
WO2014152247A9 (en) 2015-10-22
US20140294813A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
PH12017500939A1 (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd1
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA201690529A1 (ru) Способы модификации клетки-хозяина
BR112018010429A2 (pt) ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
PH12016500388A1 (en) Gitr antigen binding proteins
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
EP3741849A3 (en) Protease variants and polynucleotides encoding same
WO2015109124A3 (en) Immunomodulatory agents
AR115389A1 (es) Anticuerpo antagonista de cd73
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
GB2537077A (en) Methods for sequencing nucleic acids
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
PH12015501687A1 (en) Novel binding proteins from pcsk9
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX356162B (es) Sistema de expresion y secrecion.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]